Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.69 |
| ▸ | FAP | Q12884 | 6/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922169 | 0.91 | DPP4 (0.74) | DPP4FAPDPP9ALDH1A1 | |
| SCHEMBL5719413 | 0.89 | DPP4 (0.77) | DPP4FAPDPP9ALDH1A1 | |
| SCHEMBL3919809 | 0.86 | DPP4 (0.68) | DPP4FAPDPP9 | |
| Hydrochloric Acid SCHEMBL3974582 | 0.85 | DPP4 (0.83) | DPP4FAPDPP9 | |
| SCHEMBL3915949 | 0.83 | DPP4 (0.70) | DPP4FAPDPP9ALDH1A1 | |
| SCHEMBL3918344 | 0.83 | DPP4 (0.73) | DPP4FAPDPP9 | |
| SCHEMBL3922342 | 0.83 | DPP4 (0.77) | DPP4FAPDPP9ALDH1A1 | |
| SCHEMBL5364520 | 0.83 | DPP4 (0.65) | DPP4FAP | |
| Trifluoroacetic Acid SCHEMBL5718972 | 0.82 | DPP4 (0.68) | DPP4FAPDPP9 | |
| SCHEMBL3928140 | 0.82 | DPP4 (0.73) | DPP4FAPDPP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550455-B2 | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-23 | — | — | US | disclosed |
| US-20050130985-A1 | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130985-A1 | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition | DPP8, DPP4, DPP7 | DPP4 2/4885FAP 22/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.